Development of PI3K inhibitors: lessons learned from early clinical trials

By J. Rodón, R. Dienstmann, V. Serra, J. Tabernero. Nature Reviews Clinical Oncology, 2013

783 citations recorded by the source corpus.

Subfields: Genetics, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/ca6c5d41b9fdfae95ca54e11e598dacaa7a69de5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. M. Todaro
2. Miriam Gaggianesi
3. V. Catalano
4. A. Benfante
5. F. Iovino
6. G. Stassi
7. M. Biffoni
8. Tiziana Apuzzo

Citations in the corpus

• CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. (2014, background): “Because clinical trials with available drugs targeting PI3K or HGF pathways have not been designed in the adjuvant setting, these findings may have considerable therapeutic implications (Ghiso and Giordano, 2013; Rodon et al., 2013).”